Research & Development

AAV characterization: current status and future advances
Wednesday, November 20, 2024
For the successful delivery of functional genes to patients, recombinant adenoviral-associated vectors (AAVs) are the most established and leading platform for rare and ... read more
Changing the model of care to advance CAR-T cell therapies
Wednesday, November 20, 2024
Autologous CAR-T cell therapies have already proven effective in treating hematological cancers, spurring extensive research into their potential for a wider range of ... read more
Will the future include CAR-T-similars?
Thursday, October 31, 2024
Evaluating the factors that would support or preclude the birth and expansion of biosimilar versions of CAR-T therapies read more

Legend opens new cell therapy R&D facility in Philly
The 31,000-square-foot facility is now fully operational and will support Legend’s expanding pipeline of next-generation cell therapies.
Thursday, November 13, 2025
Orbital unveils preclinical in vivo CAR-T data for autoimmune disease
OTX-201 achieved full B cell depletion in blood, spleen, and lymph nodes in a non-human primate study.
Wednesday, July 23, 2025
Vertex shares updated data for islet cell therapy in diabetes
All patients who received a full dose of zimislecel achieved ADA-recommended target HbA1c levels and 10/12 patients were insulin free.
Monday, June 23, 2025